The new Binhai area will spearhead the development of the medical industry in China
TIANJIN, China, November 30, 2021 / PRNewswire / – Here is a report from chinadaily.com.cn:
By 2025, the new Binhai area in that of northern ChinaTianjin The municipality will develop industrial clusters worth tens of billions of yuan dedicated to pharmaceuticals, biotechnology, medical devices, diagnostics and modern Chinese medicine.
It will be shaped into a highly innovative and internationally competitive drug development and manufacturing pilot area characterized by its comprehensive subdivisions and variety of comprehensive medical products.
Binhai Biomedical Industry Annual Business Revenue Expected to Reach 100 billion yuan ($ 15.44 billion) by 2025.
These ambitious goals will be made possible thanks to Binhai’s solid industrial base and good development prospects.
At present, Binhai is already an important field for the biomedical industry in Tianjin, which in turn is recognized as a national base for exports of bio-industrial, medical and health products, modern development of traditional Chinese medicine and stem cell research.
The biomedical industry is one of the strategic emerging industries in Binhai. In 2020, the output value of the district biomedical industry was 40.25 billion yuan, accounting for 64.2 percent of the city’s total biomedical production.
It brought together more than 1,500 leading biomedical companies, including Novo Nordisk, the world’s largest insulin producer, and the Tianjin International Joint Academy of Biomedicine, which showcases high-end global talent to drive research.
They have made scientific achievements in key areas, such as recombinant proteins, stem cells, and high-end medical devices. The application of intelligent technology has been gradually extended to facilitate the upgrade and modernization of production and manufacturing.
With 153 km of coastline on the eastern coast of Tianjin and home to Tianjin Port, an important China port, Binhai is an important area for the development of both the economic shore of Bohai and Beijing–Tianjin–Hebei Region. It is also an eastern starting point of the Eurasian Continental Bridge.
The area is a national pilot area for experimental reform measures and the first free trade area in North China.
Binhai issued comprehensive favorable policy packages regarding all innovative elements involved, including financial instruments and support to develop innovation-oriented enterprises, facilitate the transformation of scientific vision into products, protect intellectual property, attract qualified human resources and improve public services.
The region has also built an alliance of biomedical innovation and entrepreneurship comprising 206 medical institutions across the city. It has carried out activities to integrate industry chains, technology, capital and talent across its alliance members.
The industrial structure will be progressively optimized to achieve the region’s goal of forming industrial parks that will be dedicated to the research and production of cells, medical devices and more. Key national laboratories, leading companies and institutions will be introduced to strengthen the industrial dynamics of the region.
The region has also seen an increase in international roles and cooperation. Binhai is now attracting more international talent to further boost its biomedical industry.
View original content to download multimedia: https://www.prnewswire.com/news-releases/binhai-new-area-to-spearhead-chinas-medical-industry-development-301434661.html